CEO and Co-Founder, Alladapt Immunotherapeutics
Ashley Dombkowski, Ph.D. is the Co-Founder and CEO of Alladapt Immunotherapeutics, a biopharmaceutical company developing disease-modifying prescription therapies to treat Food Allergy. She was previously the CEO and Co-Founder of Before Brands, Inc. which she led from inception in 2015 through the consummation of a global strategic partnership with Nestle Health Science in 2019. She co-founded both Before Brands and Alladapt with Dr. Kari Nadeau, who is also the Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. Ashley has more than 20 years of experience as an operating executive, entrepreneur, and investor. Her portfolio of innovative biotechnology, medical device, consumer health and HCIT companies has included 23andMe, Adolor, Alnara, Before Brands, BioVitrum, Epizyme, iPierian, Neosil, Nevro, Rigel, Tercica, and Twist. She previously served as a Managing Director with Bay City Capital, a $1.6B health care venture capital firm. Prior to this, she served as Chief Business Officer and Vice President of Operations for 23andMe. Before joining 23andMe, she was a Managing Director with MPM Capital where she served as a member of the firm’s Investment Committee. Earlier in her career, she was an Equity Analyst for Tiger Management L.L.C. and for Dresdner RCM Global Investors. Her non-profit work has included serving as Director, Treasurer, and Chair of the Audit Finance and Budget Committee on the Board of Directors for USA Volleyball, which is recognized by the U.S. Olympic Committee as the National Governing Body for Men’s and Women’s Indoor, Beach, and Paralympic Volleyball in the United States. Dr. Dombkowski holds a Ph.D. in Mathematics from Rice University and received her B.A. in Mathematics from Wellesley College.